Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

1

Roche's fenebrutinib met the primary endpoint in a phase 3 trial against OCREVUS for primary progressive multiple sclerosis.
2

Fenebrutinib showed a 12% numerical reduction in disability progression risk compared to OCREVUS, with early treatment effects observed.
3

The strongest treatment effect of fenebrutinib was a 26% reduction in worsening upper limb function compared to OCREVUS.
4

Safety profiles were similar for both treatments, with common adverse events including infections and transient liver enzyme elevations.
5

Roche plans to submit regulatory filings for fenebrutinib in PPMS and relapsing MS following additional study results expected in 2026.

1